◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

iShares U.S. Pharmaceuticals ETF (IHE) ETF Overview

Name: iShares U.S. Pharmaceuticals ETF (IHE) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Health · DATA UPDATED 2026-08-31

iShares U.S. Pharmaceuticals ETF (IHE) is an exchange-traded fund managed by iShares in the "Health" category. It manages roughly $2 billion in assets.

The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines.

Interactive chart & fund stats →

IHE Fund Statistics

Expense ratio	0.37%
Trailing yield	1.44%
Assets under management	$2 billion
Fund category	Health
Fund family	iShares
Inception	2006-05-01

The live price chart, fund profile and news are in the interactive IHE viewer.

Other Companies in Health

IYH · iShares U.S. Healthcare ETF — $4 billion
FHLC · Fidelity MSCI Health Care Index ETF — $3 billion
IHI · iShares U.S. Medical Devices ETF — $3 billion
FBT · First Trust NYSE Arca Biotechnology Index Fund — $3 billion
ARKG · ARK Genomic Revolution ETF — $2 billion
IHF · iShares U.S. Healthcare Providers ETF — $1 billion
FXH · First Trust Health Care AlphaDEX Fund — $1 billion
PBPH · Portfolio Building Block World Pharma And Biotech Index ETF — $952 million

← IHDG All “I” companies IHF →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.